The expression level of PD-L1 was also remarkably higher in PuMRS high-risk group, suggesting that the higher expression level of immune checkpoints was related to poorer prognosis in glioma, which is consistent previous pan-cancer studies (Liu et al., 2020). The gene discussed is CD274; the disease is cancer.